MedTrace Logo

A Pilot Test of t:Slim X2 With Control-IQ Technology

NCT03368937 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-05-25

Study results available
· View outcomes & findings →

Summary

A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology

Conditions

  • Type1 Diabetes Mellitus

Interventions

DEVICE

Tandem t:slim X2 with Control-IQ Technology

Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.

Sponsors & Collaborators

  • Tandem Diabetes Care, Inc.

    collaborator INDUSTRY

  • DexCom, Inc.

    collaborator INDUSTRY

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Virginia

    lead OTHER

Principal Investigators

  • Sue A Brown, MD · University of Virginia Center for Diabetes Technology

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-08
Primary Completion
2017-12-11
Completion
2017-12-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03368937 on ClinicalTrials.gov